AR and prostate cancer: Pharmacological inhibition of AR signaling represents a compelling and conventional therapeutic strategy for prostate cancer, which leads to a >90% 10-year survival of patients with low-risk, localized prostate cancer (Spratt et al., 2016; Leach and Buchanan, 2017).